Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.
BörsenkürzelLAB
Name des UnternehmensStandard BioTools Inc
IPO-datumFeb 10, 2011
CEOEgholm (Michael)
Anzahl der mitarbeiter818
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 10
Addresse2 Tower Place
StadtSOUTH SAN FRANCISCO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94080
Telefon16502666000
Websitehttps://www.standardbio.com/
BörsenkürzelLAB
IPO-datumFeb 10, 2011
CEOEgholm (Michael)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten